KLHL7-DT: A Drug Target / Disease Biomarker (G100775104)

Target Name: KLHL7-DT

NCBI ID: G100775104

KLHL7-DT

Other Name(s): PLATAK | KLHL7-AS1 | KLHL7 divergent transcript

KLHL7-DT: A Drug Target / Disease Biomarker

The KLHL7-DT protein is a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The KLHL7-DT protein is a key component of the KLHL7 complex, which is a highly conserved family of proteins that play a crucial role in the development and maintenance of tissues and organs, including blood vessels, neurons, and immune cells. The KLHL7 complex is composed of four subunits: KLHL7-1, KLHL7-2, KLHL7-3, and KLHL7-4.

KLHL7-1, also known as KL7, is the most abundant subunit and is responsible for the formation of the KLHL7 complex. It consists of a N-terminal transmembrane domain, a coiled-coil region, and a C-terminal cytoplasmic domain. KLHL7-1 has been shown to play a role in various physiological processes, including cell adhesion, migration, and invasion, as well as in the regulation of cell growth and differentiation.

KLHL7-2, also known as KL7.1, is a smaller subunit that is predominantly located in the cytoplasm. It consists of a N-terminal transmembrane domain and a single extracellular loop. KLHL7-2 has been shown to play a role in various cellular processes, including cell signaling, cytoskeletal organization, and cell-cell adhesion.

KLHL7-3, also known as KL7.2, is a smaller subunit that is predominantly located in the nucleus. It consists of a N-terminal transmembrane domain and a single extracellular loop. KLHL7-3 has been shown to play a critical role in the regulation of gene expression and chromatin structure.

KLHL7-4, also known as KL7-1-like, is the smallest subunit and is responsible for the formation of the KLHL7 complex. It consists of a N-terminal transmembrane domain and a single extracellular loop. KLHL7-4 has been shown to play a role in various cellular processes, including cell signaling, cytoskeletal organization, and cell-cell adhesion.

The KLHL7-DT protein is a truncated form of the KLHL7 subunit KLHL7-1 that has been shown to have neuroprotective properties. It consists of a N-terminal transmembrane domain and a single extracellular loop. The KLHL7-DT protein has been shown to play a role in various cellular processes, including neuroprotection, neurogenesis, and neurotransmission.

In addition to its potential neuroprotective properties, the KLHL7-DT protein has also been shown to have potential drug-like properties. For example, it can be expressed and purified from human brain and spinal cord tissue and can be used as a protein fragment for various applications, including cell signaling, drug development, and biochemical assays.

The KLHL7-DT protein is also a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, it has been shown to be decreased in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be decreased in individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, the KLHL7-DT protein has been shown to be decreased in individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, the KLHL7-DT protein is a potential drug target and biomarker for the treatment of various diseases. Its neuroprotective properties and potential drug-like properties make it a promising candidate for further research and development. Further studies are needed to fully understand the role of the KLHL7-DT protein in various physiological processes and to determine its potential as a drug or biomarker.

Protein Name: KLHL7 Divergent Transcript

The "KLHL7-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL7-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets